J&J’s Imaavy: A Breakthrough in Rare Blood Disorder

The FDA on Monday cleared Johnson & Johnson’s (JNJ.N) Imaavy as the first-ever approved treatment for warm autoimmune hemolytic anemia, marking a significant expansion of the drug’s commercial footprint into a second rare-disease indication. The label extension adds a condition affecting roughly one in 8,000 people to Imaavy’s approved uses, potentially widening the drug’s addressable […]